Section Edited by Aude Chapuis, MD and Marcela V. Maus, MD, PhD
Immune cell therapies and cell engineering approaches, new targets, novel functionalities, clinical trial results, correlative studies in patients who have received cell-based therapies, novel engineering strategies (molecular switches, conditional expression, logic gating), gene-edited cells to knock out or knock in novel functions, synthetic gene circuits. Includes pre-clinical animal modeling (small and large) and clinical trials.
Proteomic and phenotypic characteristics of memory-like natural killer cells for cancer immunotherapyHelena Arellano-Ballestero, Agnieszka Zubiak, Chris Dally, Kim Orchard, Aljawharah Alrubayyi, Xenia Charalambous, Melina Michael, Robert Torrance, Trinity Eales, Kushal Das, Maxine G. B. Tran, May Sabry, Dimitra Peppa, Mark W. Lowdell
20 July 2024
Generation of non-genetically modified, CAR-like, NK cellsLoïs Coënon, Emilie Rigal, Hortense Courot, Caroline Multrier, Sara Zemiti, Jennifer Lambour, Martine Pugnière, Marion de Toledo, Guillaume Bossis, Guillaume Cartron, Bruno Robert, Pierre Martineau, Bénédicte Fauvel, Jessy Presumey, Martin Villalba
18 July 2024
Off-the-shelf CAR-NK cells targeting immunogenic cell death marker ERp57 execute robust antitumor activity and have a synergistic effect with ICD inducer oxaliplatinLiuhai Zheng, Huifang Wang, Jihao Zhou, Guangwei Shi, Jingbo Ma, Yuke Jiang, Zhiyu Dong, Jiexuan Li, Yuan-Qiao He, Dinglan Wu, Jichao Sun, Chengchao Xu, Zhijie Li, Jigang Wang
4 July 2024
Genetically engineering glycolysis in T cells increases their antitumor functionRaphaëlle Toledano Zur, Orna Atar, Tilda Barliya, Shiran Hoogi, Ifat Abramovich, Eyal Gottlieb, Noga Ron-Harel, Cyrille J Cohen
4 July 2024
Tethered IL15-IL15Rα augments antitumor activity of CD19 CAR-T cells but displays long-term toxicity in an immunocompetent lymphoma mouse modelInés Sánchez-Moreno, Aritz Lasarte-Cia, Celia Martín-Otal, Noelia Casares, Flor Navarro, Marta Gorraiz, Patricia Sarrión, Sandra Hervas-Stubbs, Lorea Jordana, Juan Roberto Rodriguez-Madoz, Jesús San Miguel, Felipe Prosper, Juan Jose Lasarte, Teresa Lozano
1 July 2024
Bendamustine is a safe and effective lymphodepletion agent for axicabtagene ciloleucel in patients with refractory or relapsed large B-cell lymphomaSushma Bharadwaj, Eric Lau, Mark P Hamilton, Anmol Goyal, Hrishi Srinagesh, Alexandria Jensen, Dasom Lee, Jayasindhu Mallampet, Sarah Elkordy, Shriya Syal, Sunita Patil, Theresa Latchford, Bita Sahaf, Sally Arai, Laura J JohnstonSee the full list of authors
1 July 2024
Distinct host preconditioning regimens differentially impact the antitumor potency of adoptively transferred Th17 cellsMegen C Wittling, Hannah M Knochelmann, Megan M Wyatt, Guillermo O Rangel Rivera, Anna C Cole, Gregory B Lesinski, Chrystal M Paulos
30 June 2024
EBV promotes TCR-T-cell therapy resistance by inducing CD163+M2 macrophage polarization and MMP9 secretionYuanyuan Chen, Dijun Ouyang, Yan Wang, Qiuzhong Pan, Jingjing Zhao, Hao Chen, Xinyi Yang, Yan Tang, Qijing Wang, Yongqiang Li, Jia He, Jin-Qi You, Yingzi Li, Chi Xu, Yan RenSee the full list of authors
17 June 2024
An innovative single-cell approach for phenotyping and functional genotyping of CAR NK cellsMatthew Ryan Sullivan, Michael Finocchiaro, Yichao Yang, Judene Thomas, Alaa Ali, Isabel Kaplan, Yasmin Abdulhamid, Eden Bobilev, Michal Sheffer, Rizwan Romee, Tania Konry
31 May 2024
Neoantigen-specific stimulation of tumor-infiltrating lymphocytes enables effective TCR isolation and expansion while preserving stem-like memory phenotypesNoam Levin, Sanghyun P Kim, Charles A Marquardt, Nolan R Vale, Zhiya Yu, Sivasish Sindiri, Jared J Gartner, Maria Parkhurst, Sri Krishna, Frank J Lowery, Nikolaos Zacharakis, Lior Levy, Todd D Prickett, Tiffany Benzine, Satyajit RaySee the full list of authors
30 May 2024